PRISTIQ Drug Patent Profile

When do Pristiq patents expire, and when can generic versions of Pristiq launch?

Pristiq is a drug marketed by Pf Prism Cv and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has twenty-two patent family members in sixteen countries.

The generic ingredient in PRISTIQ is desvenlafaxine succinate. There are sixteen drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the desvenlafaxine succinate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Pristiq

A generic version of PRISTIQ was approved as desvenlafaxine succinate by ALEMBIC on June 29^th, 2015.

Summary for PRISTIQ

International Patents:	22
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	46
Clinical Trials:	23
Patent Applications:	45
Drug Prices:	Drug price information for PRISTIQ
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PRISTIQ
What excipients (inactive ingredients) are in PRISTIQ?	PRISTIQ excipients list
DailyMed Link:	PRISTIQ at DailyMed

See drug prices for PRISTIQ

See drug sales revenues for PRISTIQ

Recent Clinical Trials for PRISTIQ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
David Steffens	Phase 4
National Institute of Mental Health (NIMH)	Phase 4
Seoul National University Bundang Hospital	Phase 4

See all PRISTIQ clinical trials

Pharmacology for PRISTIQ

Drug Class	Serotonin and Norepinephrine Reuptake Inhibitor
Mechanism of Action	Cytochrome P450 2D6 Inhibitors Norepinephrine Uptake Inhibitors Serotonin Uptake Inhibitors

Paragraph IV (Patent) Challenges for PRISTIQ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PRISTIQ	Extended-release Tablets	desvenlafaxine succinate	25 mg	021992	1	2015-05-08
PRISTIQ	Extended-release Tablets	desvenlafaxine succinate	50 mg and 100 mg	021992	12	2012-02-29

US Patents and Regulatory Information for PRISTIQ

PRISTIQ is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-003	Aug 20, 2014	AB	RX	Yes	No				Y
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-001	Feb 29, 2008	AB	RX	Yes	No				Y
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-002	Feb 29, 2008	AB	RX	Yes	Yes				Y

Expired US Patents for PRISTIQ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-003	Aug 20, 2014
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-001	Feb 29, 2008
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-002	Feb 29, 2008
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-002	Feb 29, 2008
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-001	Feb 29, 2008

International Patents for PRISTIQ

See the table below for patents covering PRISTIQ around the world.

Country	Patent Number	Title	Estimated Expiration
Panama	8539901	NOVEDOSA SAL DE SUCCINATO DE O-DESMETIL-VENLAFAXINA
Poland	212943
Eurasian Patent Organization	011451	НОВАЯ СОЛЬ СУКЦИНАТ О-ДЕСМЕТИЛВЕНЛАФАКСИНА (NOVEL SUCCINATE SALT OF O-DESMETHYL-VENLAFAXINE)
Mexico	PA03007043	NUEVA SAL DE SUCCINATO DE O-DESMETIL-VENLAFAXINA. (NOVEL SUCCINATE SALT OF O-DESMETHYL-VENLAFAXINE.)
Israel	200255	METHOD OF PREPARING O-DESMETHYL-VENLAFAXINE
Australia	782092

Market Dynamics and Financial Trajectory for PRISTIQ (Desvenlafaxine)

Last updated: January 17, 2026

Executive Summary

PRISTIQ (desvenlafaxine) is an antidepressant introduced in 2009 by Wyeth (later acquired by Pfizer) targeting major depressive disorder (MDD). Over its lifespan, PRISTIQ has witnessed fluctuating market dynamics driven by evolving treatment guidelines, competition, regulatory pressures, and patent status. Despite patent expiration in key markets, the drug maintains relevance owing to its positioning within the serotonin-norepinephrine reuptake inhibitor (SNRI) class. This report analyzes PRISTIQ's current market trajectory, therapeutic landscape, revenue contributions, competitive environment, and future outlook.

Introduction: Overview of PRISTIQ

• Generic Name: Desvenlafaxine
• Therapeutic Class: SNRI (Serotonin-Norepinephrine Reuptake Inhibitor)
• Indication: Major Depressive Disorder (MDD)
• Approval Date: 2009 in the USA
• Brand Owner: Pfizer (originally Wyeth)
• Market Approval: Major markets including US, EU, Japan

Market Dynamics

1. Therapeutic Positioning and Usage Trends

PRISTIQ was launched as an alternative to venlafaxine with potential for fewer gastrointestinal side effects. However, over time, prescribing practices for MDD shifted towards:

• SSRI dominance: Fluoxetine, sertraline, and escitalopram retained first-line status.
• SNRI competition: Venlafaxine, duloxetine have maintained significant market share.
• Emergence of novel antidepressants: Esketamine, brexanolone, and psychotherapeutic advances influenced prescribing.

2. Competitive Landscape

Drug	Class	Launch Year	Market Share (2022, US)	Status
Pristiq (desvenlafaxine)	SNRI	2009	~2%	Declining
Effexor XR (venlafaxine)	SNRI	1993	~4%	Stable
Cymbalta (duloxetine)	SNRI	2004	~8%	Declining post-patent
Lexapro (escitalopram)	SSRI	2002	~17%	Dominant
New entrants (esketamine)	NMDA receptor modulator	2019	Growing	Disruptive

Source: IQVIA, 2022 data.

3. Patent Expiration and Generic Competition

• US Patent Expiry: June 2017 for PRISTIQ’s formulation.
• Impact: Sharp decline in branded sales post-generic entry.
• Global Patent Status: Varies by jurisdiction; generics introduced in Europe and Japan later.

4. Regulatory and Reimbursement Factors

• FDA: Approved for MDD; no new indications.
• EMA (Europe): Approved for MDD.
• Reimbursement Policies: Shift toward cost-effective antidepressants has constrained PRISTIQ's formulary access.

5. Market Penetration and Prescriber Trends

Prescriptions peaked around 2014, then declined:

Year	US Prescriptions (millions)	Trend
2010	3.2	Rapid growth post-launch
2014	5.1	Peak
2018	1.4	Sharp decline
2022	0.8	Continued downturn

Note: The decline correlates with generic competition and preference shifts.

Financial Trajectory

1. Revenue Overview

Year	Global Sales (USD millions)	Notes
2009	N/A	Launch year
2014	~$500	Peak sales; post-approval growth
2017	~$150	Post-patent expiry begins
2020	~$50	Significant decline
2022	<$30	Minimal contribution

Source: Pfizer Annual Reports, IQVIA.

2. Revenue Breakdown

• US Market: Historically accounted for ~70-80% of sales.
• ROW (Rest of World): Limited impact, more affected by generic competition.

3. Cost of Goods Sold and Margins

• Branded pricing maintained until patent expiry.
• Post-generics: Gross margins fell with price erosion.
• Maintaining profitability relied on pipeline diversification and off-patent strategies.

4. R&D and Lifecycle Management

• No recent new formulations or indications.
• Limited investment post-2015, focusing instead on pipeline assets within Pfizer.

Future Outlook

1. Market Reentry and Lifecycle Strategies

Pfizer has explored lifecycle extension options:

• Line extensions: Extended-release formulations, but none widely adopted.
• Patent defenses, including patent term extensions in some jurisdictions.

2. Competition and Market Share Projections

Scenario	Description	Projected US Market Share (2025)	Key Drivers
Conservative	Limited use, driven by existing formulary	~1-2%	Generic prevalence, generics' low cost
Optimistic	Increased adoption via new formulations or indications	Up to 5%	Niche repositioning, focus on treatment-resistant cases

Sources: IQVIA, Pfizer strategic disclosures.

3. Regulatory Environment Impact

• No new regulatory approvals anticipated.
• Off-label uses or new indications unlikely due to market shifts.

4. Potential Revivals

• Market re-entry would require significant innovation or niche positioning.
• Attractive options include combination therapies or biosimilars for other indications.

Comparison with Similar Antidepressants

Parameter	PRISTIQ (desvenlafaxine)	Effexor XR (venlafaxine)	Cymbalta (duloxetine)
Launch Year	2009	1993	2004
Patent Ended	2017	2012	2013
First-line Use	Moderate	Widely used	Widely used
Peak US Sales	~$500M (2014)	~$1.2B	~$1.2B
Current Status	Declining	Declining	Declining

Summary of Market and Financial Trajectory

PRISTIQ experienced rapid growth post-launch, reaching a peak in 2014. Patent expiry in 2017 led to substantial revenue erosion due to generic competition. Despite strategically limited reinvestment, PRISTIQ maintains minor niche usage. Future prospects hinge on niche repositioning, lifecycle management efforts, or abandoning of the molecule.

Key Takeaways

• PRISTIQ's market dominance was short-lived, with peak revenues near $500 million in 2014.
• Patent expiration significantly impacted sales; generic penetration rapidly eroded market share.
• The therapeutic landscape shifted towards newer modalities, reducing PRISTIQ's appeal.
• Pfizer's pipeline strategies suggest minimal focus on PRISTIQ; the future hinges on niche applications.
• Revenue generation will likely remain limited unless innovative reapplications or formulations are developed.

FAQs

1. What led to the decline of PRISTIQ's market share?
Patent expiry in 2017 enabled generics to enter, causing price erosion and a shift in prescribing patterns favoring lower-cost alternatives, leading to rapid revenue decline.

2. Are there any ongoing developmental efforts for PRISTIQ?
No significant pipeline investments or new formulations are reported; Pfizer has shifted focus toward newer antidepressants and biologics.

3. How does PRISTIQ compare to other SNRI/antidepressants?
PRISTIQ was positioned as an alternative with a favorable side-effect profile, but it failed to sustain competitiveness amid aggressive generic pricing and newer therapies.

4. Could PRISTIQ's indications expand in the future?
Unlikely, given current approval scope and market trends. No recent regulatory filings suggest expansion or additional indications.

5. What strategies could prolong PRISTIQ's market presence?
Potential strategies include niche marketing, biosimilar development, new formulations, or repositioning within specialized therapeutic areas, though none are currently planned.

---

References

1. IQVIA. (2022). Pharmaceutical Market Data.
2. Pfizer Inc. Annual Reports (2009–2022).
3. FDA. (2009). PRISTIQ (Desvenlafaxine) New Drug Application.
4. EMA. (2010). Marketing Authorization for Desvenlafaxine.
5. Intellectual Property Office. (2017). Patent Status Reports.
6. MarketWatch. (2022). Antidepressant Market Trends.

---

Disclaimer: This analysis reflects publicly available data and does not account for proprietary Pfizer strategies or confidential market actions. Market conditions are subject to rapid change, and all projections are estimates based on existing trends.